and urine, 15 suggesting the virus has developed mechanisms to reach multiple tissues. The Centers for Disease Control has now placed ZIKV on the list of blood-borne pathogens. The detection of ZIKV in blood further raises serious concerns about the risk of transfusion-related transmission and, in particular, sparking fear about the potential for severe outcomes in at-risk recipient populations.
Z ika virus (ZIKV) is an emerging arbovirus of the Flaviviridae family. 1 First isolated from a febrile rhesus macaque in 1947 in Uganda, ZIKV has not been recognized as a major viral pathogen until ZIKV infection in pregnant women in the Americas was confirmed as the cause of microcephaly and other birth defects seen in neonates. 2, 3 Indeed, studies in mouse models confirmed ZIKV can be transmitted from the pregnant mother to the fetus. [4] [5] [6] In addition, ZIKV may be transmitted during sex [7] [8] [9] or a blood transfusion. 10 To date, ZIKV has been detected in the human central nervous system, 11, 12 blood, saliva, 13 semen,
Results
The interior surfaces of vascular and lymphatic vessels are lined with endothelium, forming an interface between circulating blood or lymph in the lumen and the rest of the vessel wall. ECs are also major components of the blood-brain barrier and part of the placental blood barrier, preventing circulating virus from entering the brain and the fetal tissues, respectively. To investigate whether ZIKV directly infects ECs, we cultured the immortalized human blood-brain barrier EC line hCMEC/D3 (human cerebral microvascular endothelial cell line), which is a well-characterized blood-brain barrier cell system. 17 The African MR766 and IbH 30656 (IbH) ZIKV strains (ZIKV AF ), as well as the South American ZIKV isolates (ZIKV SA ) PRVABC59 (PRV) and FLR, but not Dengue virus (DENV-2 strain Thailand 16681), readily infected hCMEC/ D3 cells and produced infectious virus with titers comparable to that of the C6/36 cell line (Online Figure I) .
To determine the extent of ZIKV EC infection, we used cultures of human ECs at low passages (passage numbers <7) isolated from umbilical veins (human umbilical vein endothelial cells [HUVECs] ), aorta (human aortic endothelial cells), coronary artery (human coronary artery derived endothelial cells), and saphenous vein (human saphenous vein derived endothelial cells; Online Figure II ). For comparison, we also obtained human lymphatic ECs (Online Figure III) . Low-passage ECs were inoculated with the MR766 and IbH 30656 (IbH) ZIKV strains, and the PRV and FLR. Both ZIKV AF and ZIKV SA strains, but not DENV2, infected all vascular ECs from multiple donors, with HUVECs being significantly most susceptible ( Figure 1A through 1E). Notably, ZIKV entry into vascular ECs also led to productive infection and the release of infectious progeny virus ( Figure 1B and 1D) . Although the ZIKV AF strains MR766 and IbH caused minimal morphological change, infection of HUVEC cells with the 2 ZIKV SA isolates induced significant cell death, suggesting enhanced virulence of these isolates ( Figure 2A ). The PRV isolate also formed noticeably larger plaques on plaque assays ( Figure 2B ). Indeed, when the kinetics of viral RNA replication was measured, the ZIKV SA isolates displayed faster growth rates ( Figure 2C and 2D). Although we cannot completely rule out that the African isolates have been cultured for decades in the laboratory and hence adapted to be less cytopathic, our observation is consistent with a recent report that pups born from a Brazilian ZIKV (ZIKV BR ) isolateinfected SJL pregnant mice displayed abnormalities resembling the microcephaly seen in humans. 4 These findings highlight the differences between the original ZIKV AF strain, which causes no or very mild symptoms, and the circulating ZIKV SA strains that seem to be more pathogenic. The fact that HUVECs are most susceptible and the partial cytopathic effect of ZIKV SA isolates on these cells also suggest the potential involvement of ECs during vertical transmission of ZIKV.
Because vascular ECs form physical barriers with tight junctions between cells, we conducted confocal microscopy and Western blotting to evaluate the effects of ZIKV infection on endothelium integrity. Transendothelial electric resistance was measured for the assessment of endothelial barrier function. Infection by ZIKV did not directly disrupt the tight junctions or the barrier function of HUVEC or hCMEC/D3 cells (Online Figure IV) . Therefore, we reason that the loss of endothelium integrity probably only occurs when significant cell death is caused by ZIKV infection.
ZIKV is known to utilize multiple cell surface receptors, including DC-SIGN, AXL, Tyro3, and TIM-1, to gain entry with a major role for the RTK AXL. 16 A recent single-cell expression analysis revealed that the candidate entry receptor AXL is highly expressed in neural stem cells and ECs in developing human cortex. 18 To probe into the potential involvement of AXL, we first performed flow cytometric analysis and determined the AXL expression levels on low-passage cultures of human ECs. Notably, although most ECs express AXL, HUVECs seem to express AXL to the highest level, followed by human aortic endothelial cells and human saphenous vein-derived endothelial cells ( Figure 3A) . By contrast, human coronary artery-derived endothelial cells expressed little AXL. Although we cannot completely exclude potential donor variability, the cell surface expression levels of AXL positively correlate with cellular susceptibilities to ZIKV ( Figures 1E and 3A) . AXL is an RTK that transduces signals from the extracellular matrix into the cytoplasm by binding to the vitamin K-dependent protein growth arrest-specific 6 (Gas6) gene. 19 To explore the role of AXL in the observed ZIKV infection, we conducted 3 sets of experiments. First, a polyclonal antibody that recognizes the extracellular portion of human AXL blocked the entry of virus into HUVECs and hCMEC/D3 cells ( Figure 3B) . Notably, addition of the antibody did not reduce the attachment of ZIKV to cells ( Figure 3C ) and was unable to block ZIKV infection if added 3 hours after the infection had been initiated ( Figure 3D ). These data suggest that AXL is a ZIKV entry factor required at a late stage during entry. Second, ectopic expression of AXL in 293T cells promoted ZIKV infection without enhancing virus binding ( Figure 3E , 3F, and 3H). By contrast, the kinase-dead AXL, which carries a K567R mutation that destroys an ATP-binding site and inhibits Axl phosphorylation and signaling, [20] [21] [22] is significantly impaired its ability to confer permissiveness to 293T cells ( Figure 3F and 3H). These observations reinforced the idea that AXL promotes ZIKV entry at a postbinding step and also imply that AXLmediated signaling is needed for ZIKV entry. Finally, 2 known inhibitors of AXL phosphorylation, Cabozantinib 23 and R428, 24 significantly impaired ZIKA infection of hCMEC/D3 and the HUVECs in a dose-dependent manner ( Figure 4A through 4D) . By contrast, RTK inhibitors Sunitinib malate and Sorafenib had none or marginal inhibition at one micromolar (Online Figure  V) . These results indicate that AXL RTK activity is potentially important to its function in ZIKV entry. The kinetics of R428-mediated inhibition, generated from a time-of-addition experiment, showed that the compound remained inhibitory even when added at 1 hour after the virus was added but drastically lost its effect if added at 2 hours after infection had been initiated ( Figure 4E ). Therefore, R428 interferes with a postbinding process during ZIKV entry. Of note, treatment of HUVECs with AXL inhibitors neither altered AXL cell surface expression ( Figure 4F ) nor reduced cell viability (Online Figure VC) . Figure 1 . B, A polyclonal antihuman AXL antibody (AXL pAB) blocked ZIKV infection of hCMEC/D3 (human cerebral microvascular endothelial cell line) and human umbilical vein ECs (HUVECs). Cells were preincubated with antibodies at indicated concentrations for 1 h followed by virus infection (multiplicity of infection 1) of 1 h, after which a medium change occurred. Twenty-four hours post infection, cellular RNA was extracted for real-time reverse transcriptionpolymerase chain reaction quantification of entered vRNA. The obtained results were normalized against levels of GAPDH, and the ZIKV RNA levels from cells without antibody treatment were set to 1. n=3, *P<0.05. C, AXL pAB (10 μg/mL) or control IgG was added together with ZIKV PRV isolate (multiplicity of infection 1) to HUVECs cells at 4°C for 2 h, after which cells were washed or trypsinized (positive control) before real-time reverse transcription-polymerase chain reaction quantification of bound vRNA. n=2, *P<0.05. D, AXL pAB (10 μg/ mL) was either added together with PRV at the time of inoculation (0 h) or 3 h post inoculation after virus had been removed (+3 hours). Twenty-four hours post infection, cells were lysed for ZIKV RNA quantitation. n=2, *P<0.05. E, Untransfected 293T cells or cells transfected with AXL, AXL kinase dead (KD, K567R), or control kinase PDK1 were incubated with ZIKV PRV (multiplicity of infection 1) at 4°C for 2 h. After extensive wash, bound viral RNA was quantified by RT-qPCR (n=2). F, Transfected 293T cells were inoculated with PRV (multiplicity of infection 1) and then incubated for an additional 24 h before quantification of viral RNA. n=2, *P<0.05. G, Expression of AXL on transfected 293T cells was quantified by flow cytometry using the anti-AXL antibody. H, Representative confocal images of ZIKV-infected 293T cells from F. Percentages of infection were indicated at the upperleft corners. HAoEC indicates human aortic ECs; HCoECs, human coronary artery-derived ECs; and HSaVECs, human saphenous vein-derived ECs.
Discussion
With the imminent threat of the ZIKV epidemic to pregnant women and to the global blood supply, this timely study provides mechanistic understanding of ZIKV tropism and pathogenicity. The significance of our findings is 3-fold: (1) human ECs are likely one of the principal cell types of ZKIV infection. In vivo, the release of infectious ZIKV by ECs would conceivably facilitate hematogenous dissemination of the virus and bypass the barriers that would otherwise restrict viral infection and thus reach tissues where viruses typically cannot reach. Such a route allows the virus to rapidly enter or leave the bloodstream and potentially contributes to the intrauterine and transfusion-mediated ZIKV transmission (Online Figure VI) 
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This study was sponsored by National Institutes of Health grant R01DK088787 (to T. Wang), R01HL088554 (B.E. Isakson). The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication. were pretreated with Cabozantinib, R428, were pretreated with Cabozantinib or R428 for 1 h followed by ZIKV infection (multiplicity of infection 1) of 1 h, after which a medium change occurred. Twenty-four hours post infection, cellular RNA was extracted for real-time reverse transcriptionpolymerase chain reaction quantification of ZIKV RNA. The obtained results were normalized against levels of GAPDH, and the ZIKV RNA levels from DMSO-treated cells were set to 1 (n=2; error bars, SD; *P<0.05). E, ZIKV PRV was added to HUVECs cells at 4°C and incubated for 2 h. Unbound virus was washed off with cold media, and the cells were shifted to 37°C (set as a 0-h time point) to initiate synchronous infection. At the indicated time points, 1 μmol/L R428 or DMSO was added into the media and incubated for 2 h before removal (exception is t=−2 h where R428 was added back after removal of the virus and incubated for additional 2 h before removal). Infected cells were incubated at 37°C for an additional 24 h before RT-qPCR assay of ZIKV RNA. Inhibition was calculated as 100% infection relative to infections containing no inhibitors. Fitted lines represent sigmoidal time-dependent curves (mean of n=2; error bars, SD). F, Cell surface levels of AXL on compound-treated HUVECs were quantified by flow cytometry using the anti-AXL antibody. What Is Known?
• Besides infecting the developing fetal brain, Zika virus has also been recognized as a blood-borne pathogen.
• Endothelial cells are major components of the blood-brain barrier and part of the placental blood barrier, preventing circulating virus from entering the brain and the fetal tissues, respectively.
What New Information Does This Article Contribute?
• Low passage human endothelial cells can be readily infected by Zika virus of the African and South American lineage and release infectious progeny virus.
• South American Zika virus isolates replicate faster in human endothelial cells and are partially cytopathic.
• The receptor tyrosine kinase AXL is required for Zika virus entry of endothelial cells at a postbinding step.
The endothelium is the key cellular barrier between the blood and interstitial space. We find that Zika virus use of the receptor tyrosine kinase AXL allows for entry into endothelium, in particular human umbilical vein endothelium. This work demonstrates that endothelial cells are key targets for ZIKA virus and could be a novel pharmacological target. Critically, this work (1) strongly implies that screening of the stored blood supply should be a priority because of the direct contact between blood and endothelium and (2) could explain the presence of the virus in embryos, in utero, and in stored blood. of 0.01. The cells were incubated for 7 days or until they began to die from the cytopathic effect caused by the virus. After propagation, the virus containing media was collected and centrifuged at 1500g for 5 minutes to remove extracellular debris. The supernatant was then passed through a 0.22 µm filter syringe and aliquoted before it was frozen at -80 °C for long term storage. The infectious titers of stock virus were determined by plaque assays and summarized in Online Table I . The production of DENV-2 strain Thailand 16681 has been previously published 2 .
Material and Methods

Cells
Experiments involving infectious virus were approved by SRI Biosafety Committee and conducted in a Biosafety level 2 laboratory.
Antibodies and Reagents
The pan-flavivirus anti-E protein murine monoclonal antibody D1-4G2-4-15 was produced . The data represent means of two independent experiments ± SD, each done in duplicate.
Time-of-addition assays
ZIKV was added to HUVECs at 4°C and incubated for 2 hrs. Unbound virus was washed off with cold media, and the cells were shifted to 37°C (set as 0 hr time point) to initiate synchronous infection. At the indicated time points, R428 or DMSO was added into the media and incubated for two hours prior to removal (exception is t= -2hr where inhibitors were added back after removal of the virus and incubated for additional two hours prior to removal). Infected cells were incubated at 37° for an additional 24 hours prior to quantification of ZIKV RNA by RT-qPCR. Inhibition was calculated as 100 − % infection relative to infections containing no inhibitors.
Immunoblotting
Cells were grown in 6-well plates and lysates were prepared with RIPA buffer (50 mM Tris- Lincoln, NE) was used to detect bound antibody complexes.
Statistical analysis
All experiments were independently performed at least twice times as indicated in the Figure legends. Except were specified, bar graphs were plotted to show mean ± standard deviation (SD).
Statistical analyses were performed using Prism 6. A p value of <0.05 in the Wilcoxon and Kruskal-Wallis tests was considered statistically significant. 
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